The best indicator for Biotech (XBI)
We backtested 382 indicators across daily, weekly and hourly charts on real Biotech (XBI) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Where Biotech (XBI) stands
Computed from our own daily OHLCV history, not quoted from a third party. Moving averages use closing prices; "52-week" is the last 252 trading sessions.
Lorentzian Classification
On the weekly chart, this is the strongest risk-adjusted edge we found for Biotech (XBI) over ~20.4 years — beating buy-and-hold by 0.4% CAGR.
Biotech (XBI) on the weekly chart
The timeframe our backtest found best for this asset. The chart is live market data; the results above are hypothetical and historical.
Chart by TradingView. Loading it contacts tradingview.com, which may set its own cookies — see our privacy policy.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Biotech (XBI) — trailing buy-and-hold by 5.4% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Lorentzian Classification ✓ | Weekly | 11.3% | 0.57 | -44.1% | 59.3% | 177 | 0.4% |
| 2 | Chande Momentum Osc. ✓ | Weekly | 9.0% | 0.53 | -35.5% | 52.8% | 72 | -1.9% |
| 3 | Least Squares MA ✓ | Weekly | 8.7% | 0.53 | -46.0% | 54.3% | 81 | -2.1% |
| 4 | SMA 20/80 Cross ✓ | Daily | 9.0% | 0.52 | -37.5% | 57.9% | 38 | -2.0% |
| 5 | Supertrend Fast (10,2) ✓ | Weekly | 8.5% | 0.52 | -30.5% | 52.0% | 25 | -2.3% |
| 6 | Connors RSI ✓ | Weekly | 7.7% | 0.52 | -28.9% | 72.9% | 48 | -3.2% |
| 7 | Demand Index ✓ | Weekly | 9.5% | 0.52 | -49.4% | 73.1% | 52 | -1.3% |
| 8 | Supertrend (7,2) ✓ | Weekly | 8.5% | 0.52 | -26.5% | 56.0% | 25 | -2.4% |
| 9 | Supertrend (10,2) ✓ | Weekly | 8.5% | 0.52 | -30.5% | 52.0% | 25 | -2.3% |
| 10 | Negative Volume Index ✓ | Daily | 10.3% | 0.51 | -62.2% | 45.5% | 33 | -0.6% |
| 11 | TEMA 20/50 Cross ✓ | Weekly | 8.2% | 0.51 | -29.3% | 63.2% | 19 | -2.6% |
| 12 | PMax ✓ | Daily | 8.5% | 0.51 | -42.0% | 67.9% | 28 | -2.5% |
| 13 | CCI ✓ | Daily | 8.5% | 0.5 | -36.0% | 68.0% | 103 | -2.4% |
| 14 | T3 10/40 Cross ✓ | Daily | 8.4% | 0.5 | -45.2% | 57.6% | 59 | -2.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
What it would take to beat buy & hold on Biotech (XBI)
113 of 602 tested setups beat buy-and-hold on Biotech (XBI) outright. Another 122 could get there with leverage they would survive — but 94 would be liquidated by their own drawdown before they caught it.
| Indicator | Beats B&H unlevered | Leverage needed | Leverage survived |
|---|---|---|---|
| Williams %R (50) | 1 | 1.04× | 2.54× |
| DeMarker (21) | 1 | 1.28× | 2.24× |
| DEMA 100 Trend | 1 | 1.49× | 2.26× |
| ZLEMA 100 Trend | 1 | 1.49× | 3.05× |
| Pivot Points (Standard) | 1 | 1.82× | 2.75× |
| Fibonacci Pivots | 1 | 1.94× | 2.55× |
Out-of-sample, costs included. A setup is only listed if the leverage it needs is less than the leverage its own worst drawdown survives — when it isn't, no amount of leverage gets there. Volatility drag isn't modelled, so these are the optimistic case. Every indicator, ranked this way
For Biotech (XBI), Lorentzian Classification on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More etf
Get alerted when Biotech’s signal flips
We track Biotech daily. Its backtested best indicator, Lorentzian Classification (Weekly), is long right now — we'll email you the moment that changes. Free, no spam, unsubscribe any time.